Inactive Instrument

News Hyundai Bioscience Co Ltd Korea S.E.

Stocks

Personal Products

End-of-day quote Korea S.E. Other stock markets
- ^KRW	-

May. 20	Hyundai Bioscience Discloses XAFTY IC50 Data for Ebola	CI
May. 15	Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

All News

Mentions Relevance

May. 20	Hyundai Bioscience Discloses XAFTY IC50 Data for Ebola	CI
May. 15	Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Mar. 18	Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Jan. 14	Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus	CI
Nov. 14	Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-01	Hyundai Bioscience Co., Ltd. announced that it has received KRW 15 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.	CI
25-09-23	Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 15 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.	CI
25-08-14	Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-15	Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-17	Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-11-14	Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-09-18	Breakthrough in Long COVID: An investigator-initiated trial (IIT) with Hyundai Bioscience's Xafty by UCSD	AQ
24-09-17	Hyundai Bioscience USA Signs an MOU with the University of California San Diego to Conduct an Investigator-Initiated Trial to Evaluate the Efficacy of Xafty	CI
24-08-28	Hyundai Bioscience Co., Ltd. to Conduct Phase 3 Clinical Trial for High-Risk Group of COVID-19 Patients with the Goal of Emergency Use Authorization	CI
24-08-14	Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-06-18	Hyundai Bioscience Co., Ltd. announced that it has received KRW 3 billion in funding	CI
24-06-16	Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 3 billion in funding	CI
24-05-19	Hyundai Bioscience Co., Ltd. announced that it has received KRW 18 billion in funding from Sangsangin Investment & Securities Co.,Ltd., Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank	CI
24-05-16	Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-05-15	Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 18 billion in funding from Sangsangin Investment & Securities Co.,Ltd., Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank	CI
24-04-25	Hyundai Bioscience's Antiviral for Dengue Fever to Enter Clinical Trials in Brazil	CI
24-04-25	Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-Based Metabolic Anticancer Drug Targeting P53 Mutation Cancer	CI
24-04-22	Hyundai Bioscience Announces Its Successful Result from A Preclinical Study of A Niclosamide-Based Oral Anticancer Drug to Treat Triple-Negative Breast Cancer	CI
24-04-19	Hyundai Bioscience to Carry Out Global Clinical Tests Aimed At Treating All Serotypes of Dengue Virus Infection	CI
24-03-06	Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI